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We present a comprehensive study of cytogenetic alterations that occur during the progression of clear cell renal cell carcinoma
(ccRCC). We used high-density high-throughput Aﬀymetrix 100K SNP arrays to obtain the whole genome SNP copy number
information from 71 pretreatment tissue samples with RCC tumors; of those, 42 samples were of human ccRCC subtype. We
analyzed patterns of cytogenetic loss and gain from diﬀerent RCC subtypes and in particular, diﬀerent stages and grades of ccRCC
tumors, using a novel algorithm that we have designed. Based on patterns of cytogenetic alterations in chromosomal regions
with frequent losses and gains, we inferred the involvement of candidate genes from these regions in ccRCC tumorigenesis and
development. We then proposed a new model of ccRCC tumorigenesis and progression. Our study serves as a comprehensive
overview of cytogenetic alterations in a collection of 572 ccRCC tumors from diversiﬁed studies and should facilitate the search
for speciﬁc genes associated with the disease.
1.Introduction
Cytogenetic changes underlie most genetic diseases, includ-
ing cancer. Not only are diﬀerent patterns of cytoge-
netic alterations associated with diﬀerent types of tumors,
tumors of the same type at diﬀerent stages of development
also exhibit diﬀerent cytogenetic patterns. It is commonly
accepted that tumors at early stages of development have
fewer cytogenetic alterations than tumors at more advanced
stages. Early mutations in a few key genes are believed to
drivetheinitialstepsoftumorigenesis.Keymutationalevents
are loss-of-function mutations in tumor suppressor genes
(TSGs) and/or gain-of-function mutations in oncogenes.
The resulting changes in gene function are thought to
trigger the process of tumorigenesis and set the stage for the
accumulation of more genetic abnormalities as the tumor
progresses. Here we have treated gene methylation as a
special form of mutation, for ease of description.
Mutations are rare. In the two-hit theory of cancer
formation [1], loss of TSG function occurs in two stages:
mutation of one of the two parental gene copies occurs as
the ﬁrst “hit”, followed by a second hit when a large-or-
small-scale chromosomal deletion or a structural alteration
inactivates the remaining TSG allele. Thus, TSGs are often
contained in regions having copy number loss. On the
other hand, an oncogene often gains its functionality via an
increase in gene copy number or, in some cases, activating
mutations of the gene. Therefore, an oncogene is more
likely to be contained in regions where copy numbers of
DNA sequences are ampliﬁed. Analysis of cytogenetic losses
and gains in tumor cells can thus identify potential tumor
suppressors and oncogenes.
Advances in technology now allow for cytogenetic anal-
ysis in unprecedented detail. Detailed cytogenetic analysis of
ag i v e nt u m o rt y p ea td i ﬀerent stages of progression will be
necessary for a full understanding of tumor development.2 Advances in Bioinformatics
Cytogenetic proﬁling of diﬀerent tumor subtypes can also
shed light on the understanding and diagnosis of cancer by
revealing genetic alterations speciﬁc for each subtype. In this
study, we undertook a comprehensive survey of cytogenetic
losses and gains occurring in renal cell carcinoma (RCC)
by using the high throughput high density Aﬀymetrix 100K
SNP chips.
RCC is a heterogeneous disease consisting of multiple
subtypes. The most common RCC subtype is clear cell
(ccRCC), accounting for about 70% of all RCC tumors.
Other subtypes include papillary (PA, ∼10%), chromophobe
(CH, ∼5%), oncocytoma (ON, <1%), and collecting duct
carcinomas (very rare) [2, 3]. Despite large-scale genomic
screening, the only gene that is commonly mutated is the
von Hippel-Lindau (VHL) gene [4]. Mutations, methylation,
and/or LOH of the VHL gene are frequently observed in
ccRCC tumors (∼90%). Cytogenetic proﬁling of various
RCC subtypes has been studied indirectly through genome-
wide gene expression proﬁling [2, 5, 6]. Traditional methods
such as comparative genomic hybridization (CGH) [7–12],
quantitative PCR [13], ﬂuorescent in situ hybridization
(FISH), and cytogenetic banding [14, 15] have also been
applied. Only recently has the use of high-throughput high
density DNA microarray chips become available for detailed
genome-wide cytogenetic alteration study. These microar-
rays oﬀer higher resolution than traditional methods. For
example, we recently used such high density microarrays to
proﬁle genome-wide cytogenetic alterations in ccRCC and
papillary RCC [16] and Beroukhim et al. combined both
500K SNP data and gene expression data to identify the
cytogenetic alterations in VHL and sporadic tumors [17].
However,littleisknownaboutthespeciﬁcsequencebywhich
genetic alterations take place during ccRCC progression.
The most relevant study to our current one is from Jiang
et al., who relied on comparative genomic hybridization
data to construct an evolutionary tree model for RCC [18].
To our knowledge, there have been no systematic studies
characterizing progressive cytogenetic alterations in ccRCC
development using high-throughput high-density 100K SNP
microarray data.
Here we report a systematic study of cytogenetic
alteration proﬁles in ccRCC tumors at diﬀerent stages of
development and in association with tumor grades. Our
study provides a detailed map of the sequence of cytogenetic
alterations that occur during the progression of ccRCC.
Based on these results, we propose a new model of ccRCC
tumor genesis and progression. Our results suggest the
involvement of cytogenetic alterations seen in ccRCC, and
will aid in the identiﬁcation of genes relevant to ccRCC.
2.MaterialandMethods
2.1. Tissue Collection. 71 pretreatment tissue samples were
collected from multiple cancer centers, including Spectrum
Health Hospital in Grand Rapids, MI (31 cases), and the
Cooperative Human Tissue Network (CHTN, 38 cases) over
the past few years. There were 42 cases of ccRCC, 6 cases
of chromophobe, 8 cases of oncocytoma, and 15 cases of
papillary RCC. Clinicopathological information for the 42
ccRCC patients was summarized in Table 1.A l lt u m o r sw e r e
primary and sporadic in that the patients did not have a
known familial history of their tumor types. The tissues
were pulverized under liquid nitrogen and genomic DNA
was prepared by a standard protocol using proteinase K/SDS
lysis followed by phenol/chloroform extraction and ethanol
precipitation. The clinicopathological diagnosis of tumors
followed the standard TNM diagnosis of RCC. Tumor
stagingandgradingaswellasotherpathologicalfactors(e.g.,
vein or vascular invasions, necrosis or sarcomatoid factors,
etc.) were obtained from review of the pathology staining
reports and evaluation of the case notes by individual
clinicians. In particular, the diﬀerence between T1a and T1b
tumors is largely in the tumor size. Readers can refer to the
American Cancer Society for more information on tumor
staging criteria (http://www.cancer.org/). VHL mutations
were obtained through sequencing of all three exons of the
gene.
In addition to our current study, we also selected 5 large-
scale cytogenetic studies in the literature for a combined
study. Out of the 5 studies, 3 had tumor stage information,
2 did not. There were 572 ccRCC samples in total with
diﬀerent techniques used to detect cytogenetic alterations.
The clinicopathological information was summarized in
Table 1.Thecopynumberanalysisbasedontumorstageswas
summarized in Table 2.
2.2. DNA Preparation. We used Aﬀymetrix 100K SNP chips
to obtain genomic information. Each 100K SNP chip
contains two subchips using either XbaIo rHindIII to
digest the genome materials. Digestion of the DNA, PCR,
and scanning followed the instructions from Aﬀymetrix
(http://www.aﬀymetrix.com/). All data samples passed the
quality controls both before application to the chip and after
scanning the hybridized chip.
2.3. SNP Data Analysis. Raw SNP copy numbers were
calculated based on CNAG software version 2 [21]. We
used a total of 56 normal samples to obtain the normal
copy number 2 signal. Among them, 48 were downloaded
from Aﬀymetrix and 8 were obtained from our own scans
on normal kidney tissues that we have collected. The raw
copy numbers were replaced by running t-test statistics
(with a window size of 31 SNPs for the moving windows).
The t-test makes use of the copy number’s local constant
property, which assumes that the losses or gains of SNP
copy numbers tend to happen in segments. Neighboring
SNPs tend to have the same copy numbers. Thus, by
borrowing the information from its neighbors, this copy
number calculation will increase its power of uncovering
the underlying DNA alterations and decrease noise. This
operation is equivalent to smoothing the calculated raw copy
numbers. The correction is necessary because DNA samples
of tumor tissues prepared for SNP runs were generally not
a homogenous collection of tumor cells, but rather a mixed
collection of tumor and other cells (e.g., stroma). Even the
tumor cells may have diﬀerent cytogenetic patterns withAdvances in Bioinformatics 3
Table 1: Summary of clinicopathological characteristics of ccRCC samples.
#Samples
Studies Current Katte et al. 09
[14]
Beroud et al. 96
[13]
Gunawan et al.
01 [15]
Toma et al. 08
[19]
Yoshimoto et al.
07 [20] Total
Study Size 42 246 118 118 22 26 572
Gender
M 14 170 81 60 13 21 359
F 22 76 37 58 9 5 207
Total 36 246 118 118 22 26 566
Age (years)
median 64.5 60.4 62 64 59 25 62
range 39–85 24–86 26–82 32–81 35–80 46–85 24–86
Stage
pT1a 10 pT1 121 77 49 9 19
pT1b + T2 12 pT2 25 14 12 7 2
pT3a 9 pT3 97 22 34 5 2
pT3b + T4 7 pT4 3 5 23 1 2
Total 38 246 118 118 22 25 567
Fuhrman Grade
13
2 12 I 29 13 42 2 2
2-3 5 II 106 61 63 15 9
3 10 III 84 33 12 5 10
3-4 8 IV 27 11 0 0 5
42
Total 40 246 118 117 22 26 569
Size (cm)
median 5 6.6 6.6 6.67 NA NA 6.6
range 1.1–12.5 1–19 1–16 1.5–25 NA NA 1–25
NA: data not available.
diﬀered combinations of numbers of signal for the target
over signals for the control (such as 3:2, 2:3, etc.). For
example, the low-grade and early-stage tumors tend to have
a lower proportion of tumor cells than the high-grade and
later-stage tumors. We call this phenomenon partial gain or
partial loss, as opposed to complete gain or loss in that all
cells used for microarray scan are tumor cells. As a result,
without any corrections, the ﬁnal raw copy numbers of the
tumor cells would be a weighted mixture distribution of
all the components of cells prepared for the scan, usually
pulled toward the normal copy number of 2. A solid cutoﬀ
to claim a gain or loss will be improper if one takes this into
consideration.
2.4. Statistical Methods. The smoothed copy numbers were
then summarized based on cytoband using the regional
expression bias (reb) package in Bioconductor [22], adapted
to the SNP data. Brieﬂy, the algorithm grouped the probes
b yt h ea s s o c i a t e dS N Pl o c a t i o n s ;f o re a c hr e g i o n ,ag e n e r a l
test (such as binomial or t-test) was applied to determine
if the raw copy numbers in the region were collectively
higher or lower than that of normal. The test statistics were
then output for each tumor sample and for each cytogenetic
region. Disease-speciﬁc survival was used and was deﬁned
to be the time from ﬁrst operation date to either death
or last known follow-up date. For each cytogenetic region
with cross sample interquartile range of the summarized
cytogenetic alteration scores (the scores were the output
from algorithm reb for each tumor and for each cytogenetic
region) greater than 2.5, a number of survival models were
built to associate the patients’ survival with the summarized
cytogenetic alteration scores. We set the number of models
to be 100 for each cytoband. Each model was built on a
randomly selected but ﬁxed number of subset of ccRCC
patients. The score test was used to calculate the prognostic
signiﬁcance of P-values for the association. The transformed
P-values (−log10(p)) were averaged over that from the
100 models as the ﬁnal signiﬁcance of association for the
cytoband, as well as the regression coeﬃcients. A studentized
testwasusedtotestthediﬀerenceofsummarizedcytogenetic
a l t e r a t i o n sb e t w e e nt w og r o u p so fs a m p l e s .
2.5. Display of Copy Number Gains or Losses for a Group
of Samples through Boxplot. To display the collective copy4 Advances in Bioinformatics
Table 2: Selected large-scale cytogenetic studies of ccRCC tumors.
Studies Klatte et al.
09
Beroud et al.
96
Gunawan et al.
01
Toma et al.
08
Yoshimoto et al.
07 Current Total
Methods GPG qPCR G-Banding SNP10K BACPAC SNP100K
# samples 246 118 (cc only) 118 22 26 42 572
Event Stage Number of events/Total Number of samples = percent
−3p
S1 77/121 = 64% 52/77 = 68% 48/49 = 98% 19/22 = 86% 196/269 =
73%
S2 17/25 = 68% 10/14 = 71% 12/12 = 100% 2/2 = 100% 41/53 = 77%
S3 53/97 = 55% 15/22 = 68% 33/34 = 97% 14/15 = 93% 115/168 =
68%
S4 0/3 = 0% 2/5 = 40% 23/23 = 100% 1/1 = 100% 26/32 = 81%
Sum 147/246 =
60% 79/118 = 67% 116/118 = 98% 20/22 =
91% 21/26 = 81% 36/40 = 90% 419/570 =
74%
+5q
S1 28/49 = 57% 10/22 = 45% 38/71 = 54%
S2 6/12 = 50% 2/2 = 100% 8/14 = 57%
S3 23/34 = 67% 7/15 = 47% 30/49 = 61%
S4 10/23 = 43% 0/1 = 0% 10/24 = 42%
Sum 82/246 = 33% 67/118 = 57% 10/22 =
45% 15/26 = 58% 19/40 = 47% 193/452 =
43%
−14q
S1 24/121 = 20% 19/77 = 25% 29/49 = 59% 5/22 = 23% 77/269 = 29%
S2 8/25 = 32% 4/14 = 29% 9/12 = 75% 0/2 = 0% 21/53 = 40%
S3 36/97 = 37% 8/22 = 37% 22/34 = 65% 7/15 = 47% 73/168 = 43%
S4 0/3 = 0% 3/5 = 60% 14/23 = 61% 0/1 = 0% 17/32 = 53%
Sum 68/246 = 28% 34/118 = 29% 74/118 = 63% 8/22 =
36% 9/26 = 35% 12/40 = 30% 205/570 =
36%
+7 64/246 = 26% 22/118 = 19% 7/22 =
32% 9/26 = 35% 17/40 = 42% 119/452 =
26%
−8p 49/246 = 20% 39/118 = 34% 10/40 = 25% 98/404 = 24%
−6q 42/246 = 17% 28/118 = 24% 6/22 =
27% 8/26 = 31% 7/40 = 17% 91/452 = 20%
−9p 40/246 = 19% 28/118 = 24% 7/22 =
32% 5/26 = 19% 7/40 = 18% 87/452 = 19%
−4p 32/246 = 15% 17/118 = 14% 2/40 = 5% 51/404 = 13%
number gains or losses for a group of samples, we ﬁrst
calculated for each sample and for each cytoband, the
summarization scores of copy numbers of SNPs within
the cytoband through reb algorithm, which was described
previously on the smoothed copy numbers. A positive value
represents a gain, while a negative value represents a loss
for the cytoband. The absolute values represent the degrees
of losses or gains. The data from each cytoband over all
samples in the group were then summarized and a box was
produced to represent the summarization. The boxes were
placed side by side ordered by their physical positions on the
chromosome, from p-arm to q-arm, from chromosome 1 to
22. We omitted analysis for chromosome X. The upper and
the lower bounds of the boxes are the third and ﬁrst quartiles
ofthedatasequences.Iftheboxiswellbelowzero,itindicates
that the majority of the samples in the group have losses in
their copy numbers in the cytoband (at least 75%). If the box
is well above zero, it is interpreted as majority of the samples
in the group have gains in their copy numbers (at least 75%
again). Thus the boxes contain both the frequency and the
intensity of the gain or loss events in the group. It is a natural
combination of information for both. The vertical length
of the box reﬂects the range of sample CNA (cytogenetic
alteration numbers) values: the longer the box, the more
variable the range of sample values. Thus, short box lengths
reﬂect a tighter clustering of SNP copy number values than
do longer box lengths. The midpoint of each box represents
the median CNA value for all samples. An illustration ﬁgure
was displayed in Figure 1.
2.6. Determination of Losses or Gains of Chromosome Arms.
To determine loss or gain of a speciﬁc chromosome arm for
a speciﬁc sample to produce Table 2 for the current study,
we used a cutoﬀ value of 10 on the cytoband summarized
copy number data that were output from running the reb
algorithm. A value larger than 10 was marked a gain for theAdvances in Bioinformatics 5
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Figure 1: Illustration of algorithm for obtaining and displaying the cytoband summarized SNP copy number scores for a group of samples.
(a) Display of raw SNP copy number alterations for individual tumor samples. Each horizontal line in the ﬁgure represents data from one
tumorsample(totalofﬁvetumorsamplesdisplayed).RawSNPcopynumbersaredisplayedinlog2scaleandplottedontheY-axis.Negative
copynumbers(indicatingSNPlosses)aredepictedinblueandpositivecopynumbers(indicatingSNPgain)aredepictedinpink.TheX-axis
represents the physical ordering of individual SNPs along diﬀerent chromosomes. (b) Display of smoothed SNP copy number alterations
for individual tumor samples. Each horizontal line represents data from one tumor sample (total of ﬁve tumor samples displayed). (b) the
smoothed copy number by moving t-test with window size 31, (c) the cytoband summarized SNP copy number scores using the adapted
regional expression bias algorithm, and (d) boxplot of the summarized SNP copy number scores.6 Advances in Bioinformatics
whole cytoband for the sample, while a value less than −10
wasmarkedalossforthecytoband.Theproportionsoflosses
or gains for each cytoband across all tumors in the study
group were calculated. The proportion of loss (gain) of an
arm was determined to be the highest loss (gain) proportion
among all cytobands within the arm. If the proportion of
loss was higher than that of gain, the arm was an overall
lossandviceversa(undecidedcaseswhenthelossproportion
equals to the gain proportion are unlikely to happen for the
selected arms). The numbers and proportions of losses or
gains for selected chromosome arms calculated this way were
then summarized in Table 2.
3. Results
3.1. RCC Tumor Subtypes have Distinct Cytogenetic Alteration
Proﬁles. First, we compared the cytogenetic proﬁles of the
four RCC subtypes: clear cell, papillary, chromophobe,
and oncocytoma (Figures 2(a) and 2(b)). Unsupervised
clustering of tumor samples based on their cytogenetic data
revealed four clusters in the plot, roughly corresponding
to the four RCC subtypes. Tumors of a given subtype
generally clustered together. For example, all tumors of
clear cell type clustered together, with the exception of
one case which clustered with chromophobe samples. Our
results indicate that each RCC subtype displays a distinct
cytogenetic alteration proﬁle (Figure 2(a)). This cytogenetic
proﬁling correctly predicted tumor subtypes with an overall
accuracy of 92% (65/71). Although we cannot be certain, we
speculatethattumorsmisclassiﬁedbythisanalysishadmixed
features or were misdiagnosed.
3.2. −3p, +5q, and −8p Are Unique Events for ccRCC. Com-
paring cytogenetic proﬁles of four RCC tumor subtypes, we
found that −3p, +5q and −8p are unique to ccRCC tumors
(Figure2(b)).Tumorsubtypeswerelistedinincreasingorder
of cytogenetic complexity, from having the least alterations
(oncocytoma) to the most ones (chromophobe). Apart from
oncocytoma, which is a benign tumor and does not possess
any obvious cytogenetic changes, +7, +12, and −16 were
seen to occur in all other RCC subtypes, but to varying
degrees. This suggests there may be common cytogenetic
alterations aﬀecting shared signaling pathways in these RCC
subtypes. Interestingly enough, we observed that there were
no regions having copy number losses which were common
to all three malignant RCC tumors. −14q was seen in
ccRCC and papillary RCC only, while +14q was seen in
chromophobe RCC. −3p was seen in ccRCC tumors only,
while +3p was seen in papillary RCC tumors and 3p was
unchanged in chromophobe RCC. Therefore, it is likely that
each RCC subtypes has a distinct tumor initiation (such
as gene mutations) patterns, especially for TSGs if they are
involved in the development of RCCs. As the VHL gene is
located on 3p25-26, this indicates that deregulation of VHL
pathway is involved for ccRCC development only, but not for
theothertumorsubtypes.Thus,diﬀerentRCCsubtypeshave
uniquecytogeneticalterationsaswellascommonalterations.
As ccRCC accounts for the majority of RCC tumors, we will
focus our analysis on this subtype only in the rest of paper.
3.3. −3p, +5q, +7, and −14q Are Associated with Early Tumor
Stages of ccRCC. Tumor stage is an important factor in
determining tumor progression. We grouped ccRCC tumors
and analyzed their cytogenetic alteration proﬁling according
to tumor stages (Figure 3(a)). As was expected, we saw
that cytogenetic alteration events increased as tumor stage
increased. Tumors at the earliest stage, S1a, had the least
cytogenetic alterations with −3p, +5q, +7, and −14 only,
while tumors at the latest stages, S3b + S4 (the only case of
stage 4 tumor was merged with S3b) had the most cytoge-
netic alterations, notably −1p, +1q, −3p, +5q, −6q, +7, −8p,
+8q, −9, +12, −13, −14, −18, +20, and −22. This agrees
with the prevailing model of tumorigenesis and progression:
as tumor progresses, initial simple genetic events (sequence
mutations, segmental losses or gains) trigger more and
more cytogenetic alterations through altering the tumor cell
microenvironment, causing the tumor genome to become
less stable. Loss in chromosome 17 has been previously
reported to be associated with later stage events of RCC [23];
however, in our samples, we did not ﬁnd obvious loss or gain
of whole and/or part of chromosome 17.
3.4. −3p and +5q Are the Most Frequent Events for ccRCC
Tumors and Are Weakly Related. Our data suggest that −3p
and +5q are universal events in all stages of ccRCC tumors
(Figure 3(a)) and in all grades of tumors (Figure 3(b)). In
other word, they appeared to be unrelated to tumor stage
andgrade.Inlaterstages,lossesin3pwerelargelyunchanged
in frequencies (around 70%–80%, Table 2), but gains in
5q occurred with varied frequencies and degrees (Table 2
and Figure 3(a)). The two events appeared to be weakly
inversely related to each other (Pearson’s correlation test
with correlation coeﬃcient = −0.25, P =.12). As unbalanced
translocations between 3p and 5q were frequently observed
[24], this result implies the possibility of 5q gain without 3p
loss or vice versa. Indeed, Podolski and colleagues studied
5q gains intensely, found that there was a high frequency
in an unbalanced translocation between 3p and 5q, leading
to the 3p loss of one of its parental copies and 5q gains. 5q
gain could also occur in independent ways to 3p loss, such as
to have unbalanced translocations with other chromosomes
[25]. The most frequent losses on 3p were 3p26, 3p24,
3p14 and 3p21-22 for the early-stage tumors (Figure 3(a)
and Supplementary Figure S1A in supplementary material
available online at doi:10.1155/2010/428325, detailed plot of
3p is not shown). +5q occurred most frequently for stage
1a tumors at 5q31-5qter. It reached its peak at intermediate
stages (S1b and S2), then started to decrease at later stages
of S3 and S4. This observation gives partial support of the
previously reported result that 5q gain was associated with
good prognosis of ccRCC patients [24, 25]. We will discuss
this in more detail in the following section.
3.5. 5q Gain Is Likely Involved in the Transition from Stage
1a to Stage 1b Tumors and May Play a Critical Role in
ccRCC Development. The proﬁles of cytogenetic alterations
between stage 1a and stage 1b tumors were remarkably
similar (See Figure 3(a) and Supplementary Figures S1A,Advances in Bioinformatics 7
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Figure 2: (a) Unsupervised clustering of RCC samples based on cytoband summarized SNP data. CH: chromophobe RCC, PA: papillary
RCC; ON: oncocytoma, CC: clear cell. With few exceptions, tumors of a given subclass clustered together. Thus, each of the four RCC
subtypes has a distinct pattern of cytogenetic alterations. (b) Somatic cytogenetic alteration proﬁles of RCC subtypes. RCC subtypes are
ordered by complexity of molecular cytogenetic alterations. Each bar in the plot is a box with upper and lower bound of the box representing
the third (75%, upper bound) and ﬁrst quantiles (25%, lower bound) over the summarized SNP copy numbers by cgma method. The boxes
are ordered from p-arm to q-arm followed by another chromosome. Only the somatic chromosomes are shown here. A positive value stands
for gain, while a negative value stands for loss. Each chromosome is assigned a single color diﬀerent from its neighbor chromosomes.
S1B). A formal studentized t-test was used to test the
diﬀerence of cytogenetic alterations between the two groups
oftumorshavingstages1aand1b.Ateststatisticbelow −2or
above 2 was used to declare the diﬀerences to be signiﬁcant.
The proﬁle of test P-values was plotted in Supplementary
Figure S1C. The identiﬁed cytogenetic alterations declared
to be signiﬁcant between tumor groups S1a and S1b were
3p (p25–p22), 5q (q34-q35), 4q23, 11q24 and 17q22. Apart
from the single cytoband on chromosomes 4, 11, and 17,
the most signiﬁcant diﬀerences were recognized as more
gains in 5q and more losses in 3p in stage 1b tumors than
in stage 1a tumors. Unlike gains in chromosome 7, +5q is
seen to be unique to ccRCC tumors (Figure 2(b)); it occurs
in a large proportion of ccRCC tumors (43%, Table 3).
To ﬁgure out in more details, we then used a 3cm and
7cm as criteria for grouping the tumors into one of the
small-sized (<3cm), medium-sized and large-sized (>7cm)
groups. The cytogenetic alteration proﬁle of the 9 small-
sized tumors was compared with those of medium- or large-
sized tumors (Supplementary Figures2D–2F. The proﬁles
for the small and medium sized tumors were remarkably
similar, with the only striking diﬀerence occurred in 5q,
where there were no obvious gains in the small sized tumors
and where there were a signiﬁcant more 5q gains in the
medium sized tumors. Therefore, a critical role can be
proposed for genes in this region during ccRCC formation,
whose gene disruptions promote the tumor growth in size
and diﬀerentiate the kidney tumor cells into well-deﬁnedAdvances in Bioinformatics 9
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Figure 3: (a) Somatic cytogenetic alteration summarization based on SNP data, grouped by patient tumor stages in increasing order. Box
plots were arranged as in Figure 2. The earliest stage S1a shows the fewest cytogenetic alterations, while the highest stage S3b4 shows the
largest number of cytogenetic changes, indicating the cytogenetic progression of ccRCC tumors. −3p, +5q, +7, −8p, and −14 are among the
earliest events during ccRCC tumorigenesis, while −1p, +1q, −4p, −6q, −9p, +12, −13, −18, and +20q are events occurring at later stages
only. (b) Somatic cytogenetic alterations associated with tumor grade. Box plots are arranged as in Figure 2.
clear cell tumors. Cancer-relevant genes on 5q include the
LOX gene, which has been shown to play an essential role
in hypoxia-induced metastasis [30], the later is triggered by
the disrupted VHL gene in the tumor cells. Other genes in
the area include PDGFRB, which plays an important role in
tumorneovascularization[43],T GFBI[16],PTTG1,DOCK2
and DUSP1 (the latter three genes were speculated based on
our internal studies), which were likely to be involved in
ccRCCprogressionanddevelopment.However,nomutation
genes were found in this region so far.
3.6. 14q Likely Contains Important TSG Genes Unrelated to
3p Loss. As we see from our data, −14q occurred in the
earliest stage and lowest grade tumors too (along with −3p,
Figures 3(a) and 2(b)); it displayed a clear increasing pattern
in occurrence frequencies along tumor stages, uncorrelated
with that of −3p occurrences (Table 3). This suggests that
−14q is likely to have occurred in an independent way to 3p
loss; it also indicates that its occurrences are also inﬂuenced
by the tumor cell environment: as later and more advanced
tumors tend to have more occurrences of −14q. Tumor
initiationandpromotionrolesinccRCCtumordevelopment
can be proposed for genes in this region. Disruptions of
one or more than one key TSG genes in this region were
likely involved during the early ccRCC tumorigenesis. At the
same time, some functionally important genes may also be
activated by other events of tumors; those genes may play
a signiﬁcant role in promoting tumor invasiveness, as was
shown in Supplementary Figure S2I and S2J. 14q contains
functionally diversiﬁed genes, critical to a few important and10 Advances in Bioinformatics
well-studied pathways, such as HIF1α (14q21-q24, [44]) and
EGLN3(PHD3, 14q13.1, [45]), both of which were shown to
be disrupted in ccRCC tumors, due to the disrupted VHL
gene functions. The heavy chains of human antibodies (or
immunoglobulins) are also located in the far end of 14q,
with often elevated activities in ccRCC tumors. On the other
hand, other known involved tumor suppressor genes in this
region were AKT1 (14q32.32, [46]) and SERPINA5 (14q32,
[31]). AKT1 gene was shown to play a pivotal role in the
AKT/PI3K signaling pathway. In summary, our data suggest
that genes in 14q play important and diversiﬁed roles in
both ccRCC formation and its development. Again, much
remains unknown about the roles the genes in this region
play during ccRCC formation and development. More study
of genes in the region is needed to better understand the
ccRCC tumorigenesis and progression.
3.7. Gain of Whole or Part of Chromosome 7 Is an Early
Stage Event of ccRCC, Independent of Tumor stage. Gain of
chromosome 7 was seen to appear in all stages (Figure 3(a)),
indicating that one or more genes on 7 may play an impor-
tant role in both tumor development and tumor growth.
Gain of chromosome 7 also occurred in tumors of all grades
except grade 1 (Figure 3(b)) .T h em o s ta c t i v ec y t o b a n dw a s
identiﬁed to be 7q21–7q31 (data not shown). These regions
contain a number of functionally important genes, including
MET (also being called HGFR, RCCP2, c-Met) in 7q31, HGF
in 7q21, EPO (Human erythropoietin gene) in 7q22, VGF
(nerve growth factor inducible gene) in 7q31 and PDGFA
(platelet-derived growth factor alpha) in 7p22 or IGFBP1
(7p13-p12).Ampliﬁcationoforactivatingmutationsinthese
genes may play a role in the development of ccRCC. Unlike
+5q, +7 was not unique to ccRCC, but that it occurs in all
malignant RCCs; a general role for genes in this region can
be suggested during RCC development, such as proliferation
and vascular invasion (Supplementary Figure S2J), leading
to poor patients’ survivals (Supplementary Figure S2A).
3.8. −1pter, +1q, −4 −6q, +8q, −9, +12, −13, −18, and +20
Are Later Stage Events in ccRCC. These events did not appear
in the early stage S1a or S1b tumors, but occurred progres-
sively as tumors advance in stage. For example, −13 and
−18 occurred only when tumor stages exceeded 2, and they
peaked at the latest stage (S3b4, Figure 3(a)). These events
also occurred in high-grade tumors only (see Figure 3(b)).
This pattern suggests that these cytogenetic alterations are
generally the consequences of tumor development due to
increased genomic material instability, rather than the cause
of it. However, these genetic alterations may still play critical
roles in tumor progression, metastasis, and/or proliferation.
In a recent study [14], the authors found that cytogenetic
alterations of −4/4p and −9/9p, among other alterations,
were signiﬁcantly associated with patients’ survivals. We will
discuss more about these regions in the coming sections.
3.9. Association between Cytogenetic Alterations in ccRCC and
Tumor Grade. Next, we grouped and analyzed cytogenetic
alterations in ccRCC by tumor grade (Figure 3(b)). The
patterns were very similar to that grouped by tumor stage.
−3p, +5q, and −14q were seen to appear in all grades of
ccRCC tumors. On the other hand, −1p36, −4, −6, +12,
−13, −18 and +20 were seen in high-grade tumors only. Of
the three tumors with grade 1, we did not see obvious +7
or −8p. −8p appeared to occur after −3p, −14q, and +5q.
Due to the small size of grade 1 tumors (3 cases), the clear
display of −8p in grade 2 tumors (12 cases), and relative
high frequency of occurrence in clear cell tumors (24%,
see Table 3), we decide that −8p is a moderate early event
in the process of ccRCC tumorigenesis. We noted subtle
diﬀerences between the patterns of cytogenetic alterations
associated with tumor grade compared to alteration patterns
with tumor stage. +7 was seen in stage 1a tumors, yet
it was not seen in grade 1 tumors. This discrepancy may
reﬂect diﬀerences in the clinical features of tumor grade and
stage.
3.10. Association of Cytogenetic Alterations in ccRCC with
Patient Survivals and Other Clinical or Pathological Factors.
Next, we examined cytogenetic alterations in ccRCC tumors
inassociationwithpatientsurvivals.Theaveragedsigniﬁcant
P-values for each cytoband were plotted in Supplementary
Figure S2A. Cytobands from chromosomes 1, 2, 4, 6, 7,
8, and 13 were identiﬁed to be associated with patients’
survivals. Speciﬁc cytogenetic bands associated with patient
survivalweresummarizedinSupplementaryTable1.Among
these regions, −4p/4 and −13 were seen to be most signif-
icantly associated with poor survivals. This was conﬁrmed
in previous study [14]. +1q was seen to be correlated
with quite a few clinicopathological factors, which include
sarcomatoid element, stage, vein, and vascular invasions.
It is no surprise that +1q is associated with patients’
survivals (Supplementary Figure S2). Other regions were
also identiﬁed to have signiﬁcant prognostic signiﬁcance,
which were summarized in Supplementary Table 1.D u et o
our limited number of available cases who have follow-up
data, the results displayed here are likely to be conservative.
Associations between cytogenetic alterations in ccRCC
and other clinicopathological features, including VHL muta-
tion status, gender, tumor size, sarcomatoid elements, gross
tumor necrosis, renal vein and vascular invasions were
examined too; the signiﬁcances of tests were summarized
in Supplementary Table 2 and displayed in Supplemen-
tary Figure S2. Of the diﬀerent proﬁles associated with
diﬀerent clinical or pathological factors, the proﬁles for
tumor grade (Grade 1-2 versus Grade 3-4, Figure S2D),
for tumor stage (Stage 1-2 versus Stage 3-4, Figure S2E)
and for tumor size (size < versus≥4cm, Figure S2F) are
comparably similar, while the proﬁles for vein invasion (Yes
versus No, Figure S2I) and for vascular invasion (Yes versus
No, Figure S2J) are remarkably similar. These similarities
reﬂect the closeness of being clinicopathological factors.
We note that, interestingly, VHL mutation status is not
associated with any speciﬁc cytogenetic changes and that
+1q is associated with sarcomatoid diﬀerentiation, tumor
vein and vascular invasions as well as poor patient survivals,
indicating that some genes in this gene rich area play critical
roles in tumor progression or metastasis. The cytogeneticAdvances in Bioinformatics 11
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Figure 5: Illustration of a proposed model of ccRCC tumor formation and progression.
proﬁles between male and female patients were remarkably
similar too (Figure S2C), except that male patients were
more likely to have ampliﬁed chromosome 7 and 1q than
their female counterparts, and that female patients were
more likely to exhibit 8p loss. Further studies were needed
to verify if these diﬀerences were gender related.
4. Discussion
We have studied the whole genome cytogenetic alterations in
RCCtumorsusinghigh-densityhigh-throughputAﬀymetrix
SNP arrays. We conﬁrmed that diﬀerent subtypes of RCC
had distinct cytogenetic proﬁles, reﬂecting the heterogeneity
of RCC. We also showed that speciﬁc cytogenetic alterations
in ccRCC are associated with speciﬁc clinicopathological
features. Finally, by examining cytogenetic proﬁles from
ccRCC tumors at diﬀerent stages of progression, we will be
able to construct a detailed map of the sequential cytogenetic
changes that occur during ccRCC progression below.
Based on results in Table 2 and Figure 4 of the combined
studies, the most frequent alterations for ccRCC were
identiﬁed as −3p(74%), +5q(43%), −14q(36%), +7(26%),
and −8p(24%). In the four studies where tumor stage
informationwasavailable, −3pseemedtodisplaynopatterns
of decrease or increase in frequency as tumor stage increases,
while −14q occurrences show an increasing pattern in
frequency along tumor stages. In all studies, −14q occurred
in at least 20% of stage 1 tumors (average: 29%), then
increased in occurrence frequencies as tumor stage increases.
This indicates that −14q is among the earliest events in12 Advances in Bioinformatics
the tumorigenesis process. In our study, −8p occurred in
ccRCC tumors only and occurred in almost all grade and
stage tumors. This comparison indicates that −8p may have
occurred in early but not earlier than −3p and −14q did.
First of all, based on our experience and mouse model
s t u d ya sw e l la sp u b l i s h e dp a p e r s[ 47], we postulate that
there exist more than one independent pathway for ccRCC
tumors to form. The majority of ccRCC tumors involve
loss of function of the VHL gene, a key regulator of
the hypoxia-response pathway. Loss of function of VHL
leads to unregulated activity of HIF, a hypoxia-inducible
transcription factor. Overactivity of HIF, in turn, leads to
uncontrolled activation of the hypoxia-response pathway.
The VHL gene has been reported as mutated or methylated
in over 70% of ccRCC tumors [48]. However, studies in our
laboratory (data not shown) and that in others indicate that
more than 90% of ccRCC tumors exhibit deregulation of
the VHL pathway. This suggests an independent and parallel
event(s) to VHL gene mutation for deactivation of the VHL
functional pathway. Deactivation of VHL pathway alone is
not suﬃcient to cause the ccRCC phenotype [49, 50].
Combining all the information, we have collected, we
propose a new model of ccRCC tumorigenesis and pro-
gression. This model is illustrated in Figure 5. For the
majority of ccRCC tumors where VHL is involved, the
ﬁrst step starts when a key event (mutations, methylation,
etc.) occurs in VHL, leading to deactivation of the VHL
pathway and unregulated hypoxia response. Thereafter, the
tumor cells are constantly under altered microenvironment,
paving the way toward tumorigenesis. If later on, some
key non-VHL TSG genes from 3p, 8p, and/or 14q undergo
mutations or gene alterations, leading to the losses of
the functions of the corresponding genes, the tumor cells
then get suﬃcient potential toward tumorigenesis, ﬁnishing
the ﬁrst step of tumor formation in the sequence. In the
second step, key proto-oncogenic genes from 5q or 7 are
activated due to either genetic or nongenetic reasons, such as
gain-of-function mutations, gene regulations, or cytogenetic
gains or the sustained microenvironment alterations around
the tumor cells. Proto-oncogene mutation here is not a
necessary condition. The tumor cells at this step will transit
from previous latent state to present, from being local
to more opt to proliferate and metastasize; the general
results include a sudden increase in tumor size and further
destabilized microenvironment, triggering more genetic and
cytogenetic denormalization. Incidentally, deactivation of
the VHL pathway can itself lead to heightened activity of
VEGF and PDGF. As further genetic and cytogenetic events
accumulateandmoresignalingpathwaysarederegulated,the
tumor moves into the third step of progression, eventually
becominginvasiveandmetastatic.Webelievethatthismodel
describes the genetic progression of the majority of ccRCC
tumors, although VHL-pathway-independent mechanism of
the tumorigenesis is not excluded for a minority of tumors
(Figure 5, right-hand side). Candidate tumor suppressor
genes and/or oncogenes in this process were summarized in
Table 3, based on the literature and our experiences. Some
of these genes were well studied. Examples are the RASSF1
gene on 3p21.3 [26], FHIT on 3p14.2 [51], BHD gene on
17p11.2 [38, 39], and AKT1 gene on 14q32 [40]. The rest
of genes were selected based on either literature or results of
our internal gene expression proﬁling.
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